At RSNA 2011, Gamma Medica introduced its LumaGEM dual-head, low-dose, molecular breast imaging system. It is designed for ease of use, patient comfort and improved tumor detection in women with dense breasts.
During RSNA, the Mayo Clinic presented interim data from a 1,252-patient trial comparing molecular imaging to standard mammography in women with dense breasts. Of the 19 tumors present in these patients, 15 were detected by molecular imaging and only three by mammography. Gamma Medica said this was an 87 percent sensitivity for molecular imaging and only 20 percent sensitivity for mammography.
For more information: www.gammamedica.com